Zhejiang Huahai Pharmaceutical Co., Ltd.

XSSC:600521 Stock Report

Market Cap: CN¥25.4b

Zhejiang Huahai Pharmaceutical Valuation

Is 600521 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600521 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600521 (CN¥17.51) is trading below our estimate of fair value (CN¥54.35)

Significantly Below Fair Value: 600521 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600521?

Key metric: As 600521 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600521. This is calculated by dividing 600521's market cap by their current earnings.
What is 600521's PE Ratio?
PE Ratio22.3x
EarningsCN¥1.14b
Market CapCN¥25.37b

Price to Earnings Ratio vs Peers

How does 600521's PE Ratio compare to its peers?

The above table shows the PE ratio for 600521 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.6x
002262 Jiangsu Nhwa Pharmaceutical
22.6x17.8%CN¥26.5b
600566 Hubei Jumpcan Pharmaceutical
9.4x10.7%CN¥26.1b
000623 Jilin Aodong Pharmaceutical Group
15.4x38.1%CN¥22.1b
002821 Asymchem Laboratories (Tianjin)
38.8x29.9%CN¥28.9b
600521 Zhejiang Huahai Pharmaceutical
22.3x22.0%CN¥25.4b

Price-To-Earnings vs Peers: 600521 is expensive based on its Price-To-Earnings Ratio (22.3x) compared to the peer average (21.6x).

Price to Earnings Ratio vs Industry

How does 600521's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600521 22.3xIndustry Avg. 29.6xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600521 is good value based on its Price-To-Earnings Ratio (22.3x) compared to the CN Pharmaceuticals industry average (31.1x).

Price to Earnings Ratio vs Fair Ratio

What is 600521's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600521 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.3x
Fair PE Ratio29.9x

Price-To-Earnings vs Fair Ratio: 600521 is good value based on its Price-To-Earnings Ratio (22.3x) compared to the estimated Fair Price-To-Earnings Ratio (29.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600521 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥17.51
CN¥20.33
+16.1%
15.3%CN¥22.80CN¥15.00n/a4
Nov ’25CN¥18.55
CN¥20.33
+9.6%
15.3%CN¥22.80CN¥15.00n/a4
Oct ’25CN¥19.59
CN¥20.33
+3.8%
15.3%CN¥22.80CN¥15.00n/a4
Sep ’25CN¥16.83
CN¥20.53
+22.0%
15.8%CN¥22.80CN¥15.00n/a4
Aug ’25CN¥17.26
CN¥20.20
+17.0%
18.2%CN¥22.80CN¥15.00n/a3
Jul ’25CN¥17.11
CN¥18.50
+8.1%
17.2%CN¥21.00CN¥14.00n/a3
Jun ’25CN¥17.34
CN¥18.50
+6.7%
17.2%CN¥21.00CN¥14.00n/a3
May ’25CN¥16.75
CN¥18.17
+8.5%
16.6%CN¥21.00CN¥14.00n/a3
Apr ’25CN¥13.20
CN¥16.70
+26.5%
11.9%CN¥19.50CN¥15.00n/a3
Mar ’25CN¥13.94
CN¥16.70
+19.8%
11.9%CN¥19.50CN¥15.00n/a3
Feb ’25CN¥11.76
CN¥16.70
+42.0%
11.9%CN¥19.50CN¥15.00n/a3
Jan ’25CN¥14.67
CN¥19.80
+35.0%
19.0%CN¥24.20CN¥15.00n/a3
Dec ’24CN¥15.63
CN¥19.80
+26.7%
19.0%CN¥24.20CN¥15.00n/a3
Nov ’24CN¥15.91
CN¥19.80
+24.5%
19.0%CN¥24.20CN¥15.00CN¥18.553
Oct ’24CN¥16.95
CN¥20.70
+22.1%
16.7%CN¥24.20CN¥16.00CN¥19.593
Sep ’24CN¥17.02
CN¥20.63
+21.2%
16.4%CN¥24.00CN¥16.00CN¥16.833
Aug ’24CN¥18.61
CN¥22.96
+23.4%
26.7%CN¥29.88CN¥15.00CN¥17.263
Jul ’24CN¥18.41
CN¥22.96
+24.7%
26.7%CN¥29.88CN¥15.00CN¥17.113
Jun ’24CN¥18.51
CN¥22.96
+24.0%
26.7%CN¥29.88CN¥15.00CN¥17.343
May ’24CN¥19.58
CN¥22.03
+12.5%
27.7%CN¥29.88CN¥15.00CN¥16.753
Apr ’24CN¥20.17
CN¥22.03
+9.2%
27.7%CN¥29.88CN¥15.00CN¥13.203
Mar ’24CN¥20.85
CN¥22.03
+5.6%
27.7%CN¥29.88CN¥15.00CN¥13.943
Feb ’24CN¥21.66
CN¥22.03
+1.7%
27.7%CN¥29.88CN¥15.00CN¥11.763
Jan ’24CN¥21.86
CN¥20.25
-7.4%
19.5%CN¥24.54CN¥15.00CN¥14.673
Dec ’23CN¥20.31
CN¥20.25
-0.3%
19.5%CN¥24.54CN¥15.00CN¥15.633
Nov ’23CN¥20.72
CN¥20.18
-2.6%
19.5%CN¥24.54CN¥15.00CN¥15.913

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

7D

-3.0%

1Y

13.2%